Alto Neuroscience Inc. (ANRO)
NYSE: ANRO
· Real-Time Price · USD
3.93
0.37 (10.39%)
At close: Sep 11, 2025, 3:59 PM
3.95
0.50%
After-hours: Sep 11, 2025, 08:00 PM EDT
10.39% (1D)
| Bid | 3.71 |
| Market Cap | 106.41M |
| Revenue (ttm) | 394K |
| Net Income (ttm) | -64.86M |
| EPS (ttm) | -2.39 |
| PE Ratio (ttm) | -1.64 |
| Forward PE | -1.46 |
| Analyst | Buy |
| Ask | 4.08 |
| Volume | 109,628 |
| Avg. Volume (20D) | 185,588 |
| Open | 3.56 |
| Previous Close | 3.56 |
| Day's Range | 3.56 - 3.99 |
| 52-Week Range | 1.60 - 15.04 |
| Beta | 1.92 |
About ANRO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ANRO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ANRO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts5 months ago
+25.56%
Alto Neuroscience shares are trading higher after ...
Unlock content with
Pro Subscription
10 months ago
-69.99%
Alto Neuroscience shares are trading lower after the company announced topline results from a Phase 2b trial evaluating ALTO-100 as a treatment for major depressed disorder did not meet its primary endpoint.
3 weeks ago · businesswire.com
Alto Neuroscience to Participate in Upcoming Investor ConferencesMOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel prec...
